A clinical case series and literature review indicates that routine germline DNA testing in patients with primary or metastatic brain tumours can identify hereditary cancer syndromes and guide critical treatment choices.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.